Article
Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Dec 2024
Wei Xiangkai, Zhang Guoliang, Liu Qian, Niu Zhiyuan, Chu Chunhong, Liu Chenxue, Wang Ke, Li Lanxin, Wang Rui, Cui Wenrui, Xu Huixia, Liu Chenyang, Wang Ying, An Lei
Abstract excerpt
PURPOSE: EGFR classical mutations respond well to EGFR tyrosine kinase inhibitors. However, it is uncertain whether currently available EGFR-TKIs are effective against rare EGFR mutations and compound mutations. Herein, the effectiveness of almonertinib and alflutinib, the third-generation tyrosine kinase inhibitors developed in China, on rare EGFR S768I mutations and compound mutations is identified. METHODS: In...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.